USPTO serial 90879030
MIRAPEUTICS
Reviewed by CopyMark Law Group
Status 733Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- SETTLES LEWIS, SHAILA E
- Law office
- TMO LAW OFFICE 137
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with MIRAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $772*
Plus Government fees of $375
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CHRISTINA M. LICURSI
CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | proteins for use in manufacture; proteins for industrial use in agriculture, aquaculture, cosmetics, consumer products and nutrition products | ACTIVE | — |
| 005 | protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, artificially produced peptides and proteins for use in the treatment or diagnosis of cancer and hematological diseases and disorders, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neurodegenerative diseases and disorders, cardiac diseases and disorders, infectious diseases and disorders, skin and hair diseases and disorders, ear or nose or throat diseases and disorders, ocular diseases and disorders, sensory diseases and disorders, orthopedic diseases and disorders, respiratory diseases and disorders, reproductive diseases and disorders, gastrointestinal diseases and disorders, and fungal diseases and disorders; therapeutic pharmaceuticals, namely, artificially produced peptides and proteins for the treatment or diagnosis of cancer and hematological diseases and disorders, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, neurodegenerative diseases and disorders, cardiac diseases and disorders, infectious diseases and disorders, skin and hair diseases and disorders, ear or nose or throat diseases and disorders, ocular diseases and disorders, sensory diseases and disorders, orthopedic diseases and disorders, respiratory diseases and disorders, reproductive diseases and disorders, gastrointestinal diseases and disorders, fungal diseases and disorders, none of the foregoing pertaining to Parkinson's Disease or Restless Legs Syndrome | ACTIVE | — |
| 042 | scientific research, pharmaceutical research, medical research; biotechnology research; technical scientific consultation and product development for others in the field of biotechnology and the development of protein-based pharmaceuticals, diagnostics, biomaterials, industrial reagents, agricultural products, cosmetics, consumer products and nutrition products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Flagship Labs 83, Inc.
- Other trademarks owned by Flagship Labs 83, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named MIRAPEUTICS
- Prosecution event EEXT explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 21, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 2, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 31, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Mar 31, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 31, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 22, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 21, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 21, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 21, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 17, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 16, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 16, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 16, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 21, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 21, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 21, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 21, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 23, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 13, 2024 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Mar 13, 2024 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Mar 13, 2024 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jan 12, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 22, 2023 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Sep 8, 2022 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Aug 8, 2022 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jul 12, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 12, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 22, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 8, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 6, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 6, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 6, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 18, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 18, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 18, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 4, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |